{"entity":{"id":"nct04514419","kind":"trial","name":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","aka":[],"tldr":"A phase 3 trial of Pertuzumab in advanced solid tumours, run by BioRay Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel is a phase 3 interventional study registered as NCT04514419 by BioRay Pharmaceutical Co., Ltd., with 408 participants enrolled, started 2020-06-28 and due to reach its primary completion in 2024-09-11. Interventions recorded: HS627 and Pertuzumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04514419","url":"https://clinicaltrials.gov/study/NCT04514419"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pertuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04514419","phase":"3","setting":"A Phase III Study to Compare HS627 vs. Pertuzumab on the Efficacy, Safety and Immunogenicity in Combination With Trastuzumab and Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2 Positive Breast Cancer","sponsor":"BioRay Pharmaceutical Co., Ltd.","enrolled":408,"outcomes":[]},"route":"/trials/nct04514419/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"}]}}